Viking Therapeutics' obesity drug shows durable weight-loss benefit, shares surge


Save Story

Estimated read time: 2-3 minutes

Sept 22 — Viking Therapeutics on Tuesday said patients shifted to a less frequent dosing ​regimen of its experimental obesity treatment showed superior weight-loss maintenance in a study compared with those on placebo.

Shares of the drug developer ‌closed 35.7% higher at $40.85, marking their biggest one-day percentage gain in more than two years.

The results support ⁠the company's bid to make treatment ​less burdensome. Viking has been working ⁠on flexible dosing options with injectable and oral versions of VK2735 in ‌an effort to carve ‌out a place for itself in the fast-growing sector.

The company said ⁠on Tuesday that patients who switched to ⁠an every-other-week dosing of VK2735 maintained up to 97% of the weight they had lost during an initial 21-week treatment period, while those on a monthly dosing retained up to 90% of their prior weight loss over the following 12 weeks.

Louis Aronne, a former president of the Obesity ‌Society, said less frequent dosing could help patients stay ​on obesity medicines longer.

The obesity market is currently dominated by treatments from pharma majors Novo Nordisk and Eli Lilly, which are locked in a battle for market share through effective and convenient treatments including injections and pills.

Analysts expect the obesity market to reach $100 billion in annual sales by 2030.

Leerink Partners analyst Thomas Smith said the data reinforces VK2735's differentiated profile and ​competitive positioning, and described the drug's safety and tolerability profile as "impressively clean."

In a small ‌group treated weekly ‌for 33 ⁠weeks, patients lost an average of 21.7% of body weight, Viking said, adding that it plans to study oral maintenance dosing later in the trial.

"We believe long-term weight management will not follow a standard one-size-fits-all approach," Viking CEO Brian ‌Lian said, adding that patients ​will need a range of options to ‌personalize treatment throughout their ⁠weight-loss journey.

(Reporting by ​Padmanabhan Ananthan in Bengaluru; additional reporting by Kamal Choudhury; Editing by Shinjini Ganguli and ​Jonathan Ananda)

Most recent Lifestyle stories

Related topics

KSL.com Beyond Series
KSL.com Beyond Business

KSL Weather Forecast

KSL Weather Forecast
Play button